IONTAS applied its proprietary technology to generate a component utilised within FS222, which was subsequently licensed to F-star. The initiation of this trial adds to the growing portfolio of antibodies generated by IONTAS that are entering clinical trials.
António Parada, CEO at IONTAS (pictured), commented: “We are delighted with the progress of this molecule, the platform offered by F-star taps into the growing number of bispecific antibodies entering the clinic and we are proud to be part of this movement. We wish F-star every success with the clinical trial and hope this can be the foundation of an effective cancer treatment.”